| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© Author(s) (or their employer(s)) 2026. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, General & Internal |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Olanzapine-based vs neurokinin-1 receptor antagonist antiemetic regimens in highly emetogenic chemotherapy: Systematic review and meta-analysis of efficacy and safety
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Advaitha Mv, Nikhilesh Anand, Biacin Babu, Ayoola Awosika, Uttam Udayan, Jacqueline Mendoza, Alissa Lopez, Brahmaiahchari Rangachari, Sabyasachi Maity and Bharathi S Gadad |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ayoola Awosika, MD, Department of Family and Community Medicine, University of Illinois College of Medicine Peoria, 1 Illini Drive, Bloomington, IL 61601, United States. ayoolaawosika@yahoo.com |
| Key Words |
Carboplatin; Cisplatin; Highly emetogenic chemotherapy; Neurokinin-1 antagonist; Olanzapine |
| Core Tip |
Chemotherapy-induced nausea and vomiting commonly occur in patients receiving highly emetogenic chemotherapy, with rates over 90% without prophylaxis. Effective prevention preserves quality of life, supports treatment adherence, and reduces healthcare use. This study demonstrated that olanzapine-based regimens effectively prevent chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, with pronounced control of delayed-phase nausea. Low dose provides predictable efficacy, manageable sedation, oral convenience, and cost-effectiveness. Clinically, olanzapine should be included in first-line antiemetic protocols to improve patient comfort, reduce the need for rescue medication, and support adherence to treatment. |
| Publish Date |
2026-04-15 07:40 |
| Citation |
Mv A, Anand N, Babu B, Awosika A, Udayan U, Mendoza J, Lopez A, Rangachari B, Maity S, Gadad BS. Olanzapine-based vs neurokinin-1 receptor antagonist antiemetic regimens in highly emetogenic chemotherapy: Systematic review and meta-analysis of efficacy and safety. World J Clin Cases 2026; 14(12): 119112 |
| URL |
https://www.wjgnet.com/2307-8960/full/v14/i12/119112.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v14.i12.119112 |
